Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Raptor Pharmaceutica (RPTP)

Raptor Pharmaceutica (RPTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Raptor Pharmaceutica 7 HAMILTON LANDING SUITE 100 NOVATO CA 94949

www.raptorpharma.com P: 415-408-6200

Description:

Raptor Pharmaceutical Corp. is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to treat nephropathic cystinosis, non-alcoholic steatohepatitis (`NASH`), Huntington's Disease (`HD`), aldehyde dehydrogenase (`ALDH2`) deficiency, and a non-opioid solution designed to treat chronic pain and potentially thrombotic disorder. The company's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (`RAP`) and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

Key Statistics

Overview:

Market Capitalization, $K 769,970
Shares Outstanding, K 85,310
Annual Sales, $ 94,240 K
Annual Net Income, $ -65,220 K
Last Quarter Sales, $ 32,050 K
Last Quarter Net Income, $ -14,020 K
60-Month Beta 1.18
% of Insider Shareholders 5.60%
% of Institutional Shareholders 55.29%

Growth:

1-Year Return 60.43%
3-Year Return -38.94%
5-Year Return 86.72%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 36.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.16 on 08/04/16
Latest Earnings Date 11/03/16
Earnings Per Share ttm -0.74
EPS Growth vs. Prev Qtr 20.00%
EPS Growth vs. Prev Year 5.88%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 03/08/99

RPTP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -66.67%
Return-on-Assets % -17.89%
Profit Margin % -69.21%
Debt/Equity 57.12
Price/Sales 8.17
Price/Cash Flow N/A
Price/Book 11.34
Book Value/Share 0.79
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar